Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist. It is reversible and does not require metabolic activation.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **Post-MI (if indicated):** For patients $\ge$ 50 years old with a history of MI, ticagrelor 60 mg orally twice daily may be used for up to 12 months.
* Dosing duration is typically 12 months unless contraindicated or if ACS event recurs.
## Pediatric Dosing
* There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution in patients with moderate to severe hepatic impairment. No dose adjustment is recommended.
* **Renal Impairment:** No dose adjustment is recommended for mild, moderate, or severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Bleeding (major, minor, and other), dyspnea.
* **Serious:** Life-threatening bleeding, ventricular pauses, bradyarrhythmias, anaphylaxis.
* **Other:** Bruising, dizziness, diarrhea, headache, nausea, rash, hyperuricemia, increased creatinine.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Strong inducers (e.g., rifampin, carbamazepine) may decrease concentrations.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing concentrations of CYP3A4 substrates (e.g., simvastatin, atorvastatin).
* **Antithrombotics:** Increased risk of bleeding when used concurrently with other antithrombotic agents, including anticoagulants (e.g., warfarin, DOACs), other P2Y12 inhibitors, and NSAIDs.
* **Omeprazole:** Concurrent use may decrease ticagrelor exposure; consider administering doses at least 12 hours apart.
* **Digoxin:** Ticagrelor can increase digoxin levels; monitor digoxin levels closely.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal Function:** Monitor serum creatinine, especially in patients with pre-existing renal impairment.
* **Electrolytes:** Monitor electrolytes, particularly potassium, in patients with risk factors for arrhythmias.
* **Digoxin Levels:** If co-administered.
## Clinical Pearls
* Ticagrelor is generally preferred over clopidogrel in ACS due to faster onset, greater potency, and no need for metabolic activation, though bleeding risk may be higher.
* Dyspnea is a common side effect and can occur at any time. It is usually mild and transient and often resolves with continued treatment. If severe, consider discontinuation.
* Avoid routine co-administration with aspirin doses >100 mg.
* Discontinue ticagrelor 5 days prior to elective surgery if possible. The decision to restart ticagrelor should be based on individual patient risk for thrombotic events versus bleeding.
* Ticagrelor is not indicated for primary prevention of cardiovascular events.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines before making any clinical decisions.*
